Acesso livre
Acesso livre

HIV

M-A | Imunogenicidade, segurança e eficácia das vacinas contra HPV entre pessoas vivendo com HIV.

10 Ago, 2022 | 14:22h

Immunogenicity, safety, and efficacy of the HPV vaccines among people living with HIV: A systematic review and meta-analysis – eClinicalMedicine

 

Estudo randomizado | Seguimento pós-parto de 72 semanas de dolutegravir vs. efavirenz iniciado na gestação.

5 Ago, 2022 | 17:40h

72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study – The Lancet HIV

Conteúdos relacionados:

WHO Recommends Dolutegravir as Preferred HIV Treatment Option in All Populations

Week 96 results from a RCT: Efficacy and safety of dolutegravir or darunavir combined with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection.

RCT: Efficacy and safety of switching to the 2-drug regimen Dolutegravir/Lamivudine vs. continuing a 3- or 4-Drug regimen for maintaining virologic suppression in adults living with HIV-1.

RCT: Low-cost, easy to take antiretroviral treatment based on Dolutegravir as first- or second-Line therapy found to be non-inferior to standard care for treating HIV-1 infection in children.

RCT: Dolutegravir or Darunavir in combination with Zidovudine or Tenofovir to treat HIV.

Randomized controlled trial compared three antiretroviral regimens started in pregnant women with HIV

Randomized Trial: Switching to Dolutegravir/Lamivudine Two-Drug Regimen Noninferior to Continuing a Tenofovir Alafenamide–Based Three- or Four-Drug Regimen for Maintenance of Virologic Suppression in Adults With HIV-1

 

M-A de rede | Resumo das evidências avaliando o ganho de peso corporal entre pessoas em terapia antirretroviral para tratamento de HIV.

5 Ago, 2022 | 17:06h

Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy – a systematic literature review and network meta-analysis – eClinicalMedicine

 

Comentário no Twitter

 

Diretrizes OMS sobre prevenção, diagnóstico, tratamento e cuidado de populações-chave para HIV, hepatite viral e DST.

4 Ago, 2022 | 14:31h

Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations – World Health Organization

Comunicado de imprensa: WHO publishes new guidelines on HIV, hepatitis and STIs for key populations – World Health Organization

 

Diretrizes OMS para diagnóstico, prevenção e tratamento da doença criptocócica entre adultos, adolescentes e crianças vivendo com HIV.

6 Jul, 2022 | 11:29h

Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV – World Health Organization

Diretriz OMS para tratamento de leishmaniose visceral em pacientes coinfectados pelo HIV no leste africano e no sudeste asiático.

6 Jul, 2022 | 11:28h

WHO guideline for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia – World Health Organization

Comunicado de imprensa: Visceral leishmaniasis and HIV coinfection: WHO publishes new guideline with region-specific treatment recommendations – World Health Organization

Estudo randomizado | Em pessoas vivendo com HIV, o tratamento de lesões anais pré-cancerosas reduz mais da metade do risco de câncer anal.

22 Jun, 2022 | 21:45h

Comunicado de imprensa: In people with HIV, treating precancerous anal lesions cuts risk of anal cancer by more than half – National Institutes of Health

Estudo original: Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer – New England Journal of Medicine (link para o resumo – $ para o texto completo)

 

Comentário no Twitter

 

M-A | Benefícios e riscos do início rápido de terapia antirretroviral em pacientes com HIV.

22 Jun, 2022 | 21:10h

Benefits and Risks of Rapid Initiation of Antiretroviral Therapy: A Systematic Review and Meta-Analysis – Frontiers in Pharmacology

Panorama global do impacto de sintomas depressivos/depressão maior em indivíduos vivendo com HIV/Aids e seus efeitos sobre a adesão aos medicamentos antirretrovirais.

16 Jun, 2022 | 13:18h

The Global Landscape of the Burden of Depressive Symptoms/Major Depression in Individuals Living With HIV/AIDs and Its Effect on Antiretroviral Medication Adherence: An Umbrella Review – Frontiers in Psychiatry

Combinação de infusões de anticorpos anti-HIV suprimem o vírus por período prolongado.

14 Jun, 2022 | 13:21h

Comunicado de imprensa: Combination anti-HIV antibody infusions suppress virus for prolonged period – National Institutes of Health

Estudo original: Combination anti-HIV antibodies provide sustained virological suppression – Nature

 

Comentários no Twitter

 

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.